These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38190865)

  • 1. Clinical effect of torsemide in a horse with congestive heart failure and atrial fibrillation.
    Ferlini Agne G; Kapusniak AE; Wooldridge AA; Jung SW
    J Equine Vet Sci; 2024 Feb; 133():105001. PubMed ID: 38190865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic properties of orally administered torsemide in healthy horses.
    Agne GF; Jung SW; Wooldridge AA; Duran SH; Ravis W; Toribio R
    J Vet Intern Med; 2018 Jul; 32(4):1428-1435. PubMed ID: 29770976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of torsemide and furosemide on clinical, laboratory, radiographic and quality of life variables in dogs with heart failure secondary to mitral valve disease.
    Peddle GD; Singletary GE; Reynolds CA; Trafny DJ; Machen MC; Oyama MA
    J Vet Cardiol; 2012 Mar; 14(1):253-9. PubMed ID: 22364690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Torsemide: a pyridine-sulfonylurea loop diuretic.
    Blose JS; Adams KF; Patterson JH
    Ann Pharmacother; 1995 Apr; 29(4):396-402. PubMed ID: 7633019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Torsemide: a new loop diuretic.
    Fowler SF; Murray KM
    Am J Health Syst Pharm; 1995 Aug; 52(16):1771-80; quiz 1814-5. PubMed ID: 8528833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure.
    Noe LL; Vreeland MG; Pezzella SM; Trotter JP
    Clin Ther; 1999 May; 21(5):854-66. PubMed ID: 10397380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure.
    Gottlieb SS; Khatta M; Wentworth D; Roffman D; Fisher ML; Kramer WG
    Am J Med; 1998 Jun; 104(6):533-8. PubMed ID: 9674715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-response study of intravenous torsemide in congestive heart failure.
    Hariman RJ; Bremner S; Louie EK; Rogers WJ; Kostis JB; Nocero MA; Jones JP
    Am Heart J; 1994 Aug; 128(2):352-7. PubMed ID: 8037103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Six-week study of torsemide in patients with congestive heart failure.
    Goebel KM
    Clin Ther; 1993; 15(6):1051-9. PubMed ID: 8111802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure.
    Kramer WG; Smith WB; Ferguson J; Serpas T; Grant AG; Black PK; Brater DC
    J Clin Pharmacol; 1996 Mar; 36(3):265-70. PubMed ID: 8690821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.
    Vargo DL; Kramer WG; Black PK; Smith WB; Serpas T; Brater DC
    Clin Pharmacol Ther; 1995 Jun; 57(6):601-9. PubMed ID: 7781259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of torsemide in patients with decompensated and compensated congestive heart failure.
    Bleske BE; Welage LS; Kramer WG; Nicklas JM
    J Clin Pharmacol; 1998 Aug; 38(8):708-14. PubMed ID: 9725546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of oral administration of furosemide and torsemide in healthy dogs.
    Hori Y; Takusagawa F; Ikadai H; Uechi M; Hoshi F; Higuchi S
    Am J Vet Res; 2007 Oct; 68(10):1058-63. PubMed ID: 17916010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the loop diuretic torsemide in three dogs with advanced heart failure.
    Oyama MA; Peddle GD; Reynolds CA; Singletary GE
    J Vet Cardiol; 2011 Dec; 13(4):287-92. PubMed ID: 22030290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy in congestive heart failure: drug absorption in the management of congestive heart failure: loop diuretics.
    Sica DA
    Congest Heart Fail; 2003; 9(5):287-92. PubMed ID: 14564148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group.
    Patterson JH; Adams KF; Applefeld MM; Corder CN; Masse BR
    Pharmacotherapy; 1994; 14(5):514-21. PubMed ID: 7997385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical management of congestive heart failure in a horse.
    Brumbaugh GW; Thomas WP; Hodge TG
    J Am Vet Med Assoc; 1982 Apr; 180(8):878-83. PubMed ID: 7085465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Torasemide in chronic heart failure: results of the TORIC study.
    Cosín J; Díez J;
    Eur J Heart Fail; 2002 Aug; 4(4):507-13. PubMed ID: 12167392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of oral torasemide in dogs with degenerative mitral valve disease and new onset congestive heart failure: The CARPODIEM study.
    Besche B; Blondel T; Guillot E; Garelli-Paar C; Oyama MA
    J Vet Intern Med; 2020 Sep; 34(5):1746-1758. PubMed ID: 32767627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loop diuretics enhance the secretion of prostacyclin in vitro, in healthy persons, and in patients with chronic heart failure.
    Liguori A; Casini A; Di Loreto M; Andreini I; Napoli C
    Eur J Clin Pharmacol; 1999 Apr; 55(2):117-24. PubMed ID: 10335906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.